Roivant Sciences Ltd. (ROIV)
Free
No email, no account, no signup.
Pulling latest news for Roivant Sciences Ltd.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceutical development and commercialization
Market Cap
$20.3B
We're already tracking Roivant Sciences Ltd. — here are the latest events we've registered
Recent News
- In March 2026, Roivant reached a $2.25 billion global settlement with Moderna regarding lipid nanoparticle technology patents, with the first payment expected in July 2026. On April 2, 2026, the company announced the expansion of its brepocitinib program and reported that Phase 3 studies for batoclimab did not meet their primary endpoints. Roivant also authorized a share repurchase program of up to $1 billion following the settlement.
Want to know how this news affects Roivant Sciences Ltd.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Roivant Sciences Ltd. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.